Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma.

Cancer - 1 Apr 2017

Takeuchi Toshifumi, Yamaguchi Motoko, Kobayashi Kyoko, Miyazaki Kana, Tawara Isao, Imai Hiroshi, Ono Ryoichi, Nosaka Tetsuya, Tanaka Kyosuke, Katayama Naoyuki

Abstract excerpt

BACKGROUND: CD5-positive (CD5+ ) diffuse large B-cell lymphoma (DLBCL) is characterized by frequent central nervous system recurrence and a predominant activated B-cell-like nature. Primary DLBCL in sanctuary sites (DLBCL-SS) also demonstrates these features, and >70% of patients harbor myeloid differentiation primary response 88 (MYD88) (L265P) and CD79B mutations. The objective of the current study was to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CD79 Antigens
Share to Guanylate Cyclase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Monoclonal, Murine-Derived

Share to CARD Signaling Adaptor Proteins

Share to CD5 Antigens

Share to Prednisone

Share to Rituximab

Share to Vincristine

Source

Identifiers

PMID: 27915469
DOI: 10.1002/cncr.30404

Genes

MYD88
CARD11

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma.PMID 27915469Read ↗

Deciphering the Prognostic Significance of MYD88 and CD79B Mutations in Diffuse Large B-Cell Lymphoma: Insights into Treatment Outcomes.Semantic proximity Read ↗

MYD88 <sup>L265P</sup> and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapySemantic proximity Read ↗

Comparative Study on the Clinicopathologic and Molecular Characteristics of Primary and Secondary Diffuse Large B-cell Lymphoma in the Central Nervous System.Semantic proximity Read ↗

High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sitesSemantic proximity Read ↗

MYD88, CARD11, and CD79B Oncogenic Mutations are Rare Events in the Indian Cohort of De Novo Nodal Diffuse Large B-Cell Lymphoma.Semantic proximity Read ↗

Frequent MYD88 L265P and CD79B Mutations in Primary Breast Diffuse Large B-Cell Lymphoma.Semantic proximity Read ↗

Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical PracticeSemantic proximity Read ↗

Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations.Semantic proximity Read ↗

Frequent Gene Mutations and Their Possible Roles in the Pathogenesis, Treatment and Prognosis of Primary Central Nervous System Lymphoma.Semantic proximity Read ↗

Prevalence and prognostic value of MYD88 and CD79B mutations in ocular adnexal large B-cell lymphoma: a reclassification of ocular adnexal large B-cell lymphoma.Semantic proximity Read ↗

De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients.Semantic proximity Read ↗

Mutational frequencies of CD79B and MYD88 vary greatly between primary testicular DLBCL and gastrointestinal DLBCL.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.